Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops.

Launched by UNIVERSITÉ DE SHERBROOKE · Feb 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a special eye drop treatment called 20% autologous serum drops (ASED) for patients with corneal epitheliopathy, a condition affecting the surface of the eye, caused by glaucoma medications. Many patients using glaucoma drops experience symptoms like dry eyes due to preservatives in these medications. The trial aims to find out if ASED, which contains natural growth factors and nutrients, can help improve eye health better than a placebo (a treatment that looks the same but has no active ingredients).

To participate, you must be an adult between 18 and 90 years old, have glaucoma, and be experiencing corneal problems that haven't improved with standard treatments like artificial tears. During the study, you'll receive ASED in one eye and a placebo in the other eye for two months, while also continuing to use your regular artificial tears. Researchers will monitor your eye health and symptoms to see if ASED works better than the placebo. This trial is not yet recruiting participants, but if you meet the criteria, it could offer a new option to help alleviate your eye discomfort associated with glaucoma treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with glaucoma who developed corneal epitheliopathy secondary to antihypertensive drops;
• • Epitheliopathy refractory to conventional therapies (Artificial Tears, ointment, topical cyclosporine or punctal plug, etc.);
• • National Eye Institute score of 3 or more for both eyes;
• • Adults aged 18 to 90 years inclusively.
• Exclusion Criteria:
• • Corneal epitheliopathy of other origin (ie. mechanical, neurotrophic, toxic, post-infectious, limbal stem cell deficiency);
• • Glaucoma surgery within the last six (6) months;
• • Previous corneal surgery;
• • Active autoimmune disease;
• • Frequent contact lense wear;
• • Pregnant or actively breast-feeding;
• • Known systemic infection with HIV, hepatitis B and C or syphilis;
• • Known severe anemia (Hb \< 100 g/L);
• • Inability to give informed consent